VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
CGENCompugen Ltd.
$2.01$190M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksCGENP/E History

CGEN logoCompugen Ltd. (CGEN) P/E Ratio History

Premium Valuation

Trading at 5.3x vs 5Y avg 4.1x · 100th percentile · Premium to historical baseline · Data 2025–2025

Current P/E (TTM)
5.3x
+28% vs 5Y avg
5Y Avg P/E
4.1x
Median 4.1x
5Y Percentile
100th
Upper end of range
PEG Ratio
N/A
TTM EPS$0.37
Price$2.01
Earnings Yield18.91%
EPS Growth (1Y)337.5%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of June 22, 2026, Compugen Ltd. (CGEN) trades at a price-to-earnings ratio of 5.3x, with a stock price of $2.01 and trailing twelve-month earnings per share of $0.37.

The current P/E is 28% above its 5-year average of 4.1x. Over the past five years, CGEN's P/E has ranged from a low of 4.1x to a high of 4.1x, placing the current valuation at the 100th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, CGEN trades at a 76% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.

Relative to the broader market, CGEN trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CGEN DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

CGEN Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
5.3vs22.1
-76%
Below Sector
vs. S&P 500
5.3vs24.4
-78%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 338% EPS growth (1Y)

CGEN P/E vs Peers

Drug Discovery and Antibody Platforms peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
INVA logoINVAInnoviva, Inc.
$2B6.8Lowest0.66Best+817%Best
ILMN logoILMNIllumina, Inc.
$25B29.77.02+171%
TMO logoTMOThermo Fisher Scientific Inc.
$173B26.212.40+7%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

CGEN Historical P/E Data (2025–2025)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2025 Q4Dec 31 2025$1.53$0.374.1x+0%

Average P/E for displayed period: 4.1x

Export Data
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

1+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

CGEN — Frequently Asked Questions

Quick answers to the most common questions about buying CGEN stock.

What is CGEN's P/E ratio?

Compugen Ltd. (CGEN) trailing twelve-month P/E ratio is 5.3x, based on TTM diluted EPS of $0.37. The 5-year average P/E is 4.1x and the historical range spans 4.1x to 4.1x.

Is CGEN stock overvalued or undervalued?

CGEN trades at 5.3x P/E, above its 5-year average of 4.1x. The 100th percentile ranking within the 4.1x–4.1x historical range indicates a premium to historical valuation.

Is CGEN stock expensive?

Yes, CGEN is expensive relative to its own history. The current P/E of 5.3x is above the 5-year average of 4.1x. The stock sits at the 100th percentile of its 5-year valuation range.

What is CGEN's historical P/E range?

Over the past 5 years, CGEN's P/E ratio has ranged from 4.1x to 4.1x, with a median of 4.1x and an average of 4.1x. The current P/E of 5.3x places the stock at the 100th percentile of this range. Full historical data spans 2025–2025.

How does CGEN's P/E compare to the S&P 500?

CGEN trades at 5.3x P/E versus the S&P 500 median of 24.4x. The 78% discount to the market suggests lower growth expectations or perceived higher risk.

How does CGEN's valuation compare to Healthcare peers?

Compugen Ltd. P/E of 5.3x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is CGEN's PEG ratio?

CGEN PEG ratio is N/A, based on a P/E of 5.3x and EPS growth of 337.5%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is CGEN's earnings yield?

CGEN earnings yield is 18.91%, the inverse of its 5.3x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

CGEN P/E Ratio History (2025–2025)

Quarterly valuation multiple from closing price and trailing EPS

Current4.1x
Period Avg4.1x
Range4.1x - 4.1x
Change+0%
1 quartersDec 31, 2025 - Dec 31, 2025